← All trials
NCT05150704
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 7, 2021
- Primary completion
- Oct 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- Dec 9, 2021
- Last posted
- Dec 21, 2021
- Enrollment
- 288
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MilanLead sponsor
- Government of ItalyCollaborator
- Mario Negri InstituteCollaborator
- University of Milano BicoccaCollaborator
- Regione LombardiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.